These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29255067)

  • 1. How I treat CLL patients with ibrutinib.
    Brown JR
    Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
    Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
    Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Coutre SE; Byrd JC; Hillmen P; Barrientos JC; Barr PM; Devereux S; Robak T; Kipps TJ; Schuh A; Moreno C; Furman RR; Burger JA; O'Dwyer M; Ghia P; Valentino R; Chang S; Dean JP; James DF; O'Brien SM
    Blood Adv; 2019 Jun; 3(12):1799-1807. PubMed ID: 31196847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
    J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
    Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.
    Dimou M; Iliakis T; Pardalis V; Bitsani C; Vassilakopoulos TP; Angelopoulou M; Tsaftaridis P; Papaioannou P; Koudouna A; Kalyva S; Kyrtsonis MC; Panayiotidis P
    Leuk Lymphoma; 2019 Dec; 60(12):2939-2945. PubMed ID: 31184241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
    PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
    Ahn IE; Farooqui MZH; Tian X; Valdez J; Sun C; Soto S; Lotter J; Housel S; Stetler-Stevenson M; Yuan CM; Maric I; Calvo KR; Nierman P; Hughes TE; Saba NS; Marti GE; Pittaluga S; Herman SEM; Niemann CU; Pedersen LB; Geisler CH; Childs R; Aue G; Wiestner A
    Blood; 2018 May; 131(21):2357-2366. PubMed ID: 29483101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Spaner DE; McCaw L; Wang G; Tsui H; Shi Y
    Cancer Med; 2019 Apr; 8(4):1540-1550. PubMed ID: 30843659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
    Shanafelt TD; Parikh SA; Noseworthy PA; Goede V; Chaffee KG; Bahlo J; Call TG; Schwager SM; Ding W; Eichhorst B; Fischer K; Leis JF; Chanan-Khan AA; Hallek M; Slager SL; Kay NE
    Leuk Lymphoma; 2017 Jul; 58(7):1630-1639. PubMed ID: 27885886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
    Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
    Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
    [No Abstract]   [Full Text] [Related]  

  • 18. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
    UK CLL Forum
    Haematologica; 2016 Dec; 101(12):1563-1572. PubMed ID: 27756834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.